A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Conclusions:
Algenpantucel-L immunotherapy did not improve survival in patients with borderline resectable or locally advanced unresectable PDAC receiving SOC neoadjuvant chemotherapy and chemoradiation.
Trial Registration:
ClinicalTrials.gov Identifier: NCT01836432
Source: Annals of Surgery - Category: Surgery Tags: RANDOMIZED CONTROLLED TRIALS Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Clinical Trials | Genetics | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Surgery | Vaccines